Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
Projects that will be considered for Pfizer support will focus on:
• Studies evaluating the pneumococcal burden of disease and serotype distribution prior to, or following, the implementation of PCV immunization programs with PCV13 or PCV10 o Invasive Pneumococcal Disease (IPD) o Community Acquired Pneumonia (CAP)
• Genetic evolution of pneumococci following immunization programs with PCV13 or PCV10
• Nasopharyngeal carriage in children prior to, or following, the implementation of PCV immunization programs
• Antibiotic resistant S. pneumoniae in children prior to, or following, the implementation of PCV immunization programs
Grant Application due date: October 15, 2019